Ignite Creation Date:
2024-05-06 @ 3:09 PM
Last Modification Date:
2024-10-26 @ 1:44 PM
Study NCT ID:
NCT04541654
Status:
RECRUITING
Last Update Posted:
2024-03-20
First Post:
2020-08-25
Brief Title:
Li-Fraumeni TP53 LiFT UP Understanding and Progress
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Study Overview
Official Title:
Li-Fraumeni TP53 Understanding and Progress LiFT UP
Status:
RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LiFT_UP
Brief Summary:
The purpose of this research study is to learn more about variants in the TP53 gene both associated with Li-Fraumeni Syndrome LFS a hereditary cancer risk condition and TP53 variants found in the blood for other reasons eg ACECHIP and mosaicism
Detailed Description:
This research study looks to enroll as many people with LFS or TP53 gene variants as possible in order to
Better estimate cancer risks in individuals with TP53 variants or LFS which is a rare condition
Learn the range of cancer risks linked to TP53 variants to help individuals and families to improve our ability to counsel patients and families about cancer risks more accurately
Improve opportunities for cancer prevention early detection and treatment
Learn more about the meaning of TP53 variants in the blood that are not inherited eg ACECHIP and mosaicism
Study procedures will include
Collecting information from the participants medical record and short questionnaires
Collecting blood saliva eyebrow hair and tumor tissue samples optional
Sharing study information with family members optional
It is expected that about 1500 people will take part in this research study Participants will be in this study until it closes or the participant withdraws consent
The National Cancer Institute is providing funding for part of this study and is considered a study sponsor They will require that some of the genetic information be made available to the research community without personal identifying information
Better estimate cancer risks in individuals with TP53 variants or LFS which is a rare condition
Learn the range of cancer risks linked to TP53 variants to help individuals and families to improve our ability to counsel patients and families about cancer risks more accurately
Improve opportunities for cancer prevention early detection and treatment
Learn more about the meaning of TP53 variants in the blood that are not inherited eg ACECHIP and mosaicism
Study procedures will include
Collecting information from the participants medical record and short questionnaires
Collecting blood saliva eyebrow hair and tumor tissue samples optional
Sharing study information with family members optional
It is expected that about 1500 people will take part in this research study Participants will be in this study until it closes or the participant withdraws consent
The National Cancer Institute is providing funding for part of this study and is considered a study sponsor They will require that some of the genetic information be made available to the research community without personal identifying information
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01CA242218 | NIH | None | httpsreporternihgovquickSearchR01CA242218 |